Antibodies against epidermal growth factor receptor (EGFR) and uses thereof

US9044460B2 · kind B2 · utility

Assignee

• Merrimack Pharmaceuticals, Inc. · US

Inventors

• Raghida BUKHALID · Melrose, US
• Michael Feldhaus · Lebanon, US
• Anne KING · Cambridge, US
• Neeraj Kohli · Watertown, US
• Eric Krauland · Lebanon, US
• Ulrik Nielsen · Quincy, US

Key dates

• Filing date: May 4, 2011
• Grant date: Jun 2, 2015
• Expiry date: May 29, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.